New therapeutic options for advanced non-resectable malignant melanoma

• Published in: Advances in medical sciences Vol. 60; no. 1; pp. 83 - 88
• Main Authors: Stadler, Simone, Weina, Kasia, Gebhardt, Christoffer, Utikal, Jochen
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Urban & Partner Sp. z o.o 01.03.2015
• Subjects: Antineoplastic Agents - therapeutic use; Disease Progression; Humans; Immunotherapy; Melanoma; Melanoma - drug therapy; Melanoma - mortality; Melanoma - therapy; Melanoma, Cutaneous Malignant; Metastasis; Skin Neoplasms; Targeted therapy; Treatment; Treatment; Metastasis; Targeted therapy; Immunotherapy; Melanoma
• ISSN: 1896-1126; 1898-4002
• DOI: 10.1016/j.advms.2014.12.002

Melanoma is a malignant tumor which is inclined to metastasize promptly into the lymphatic system and other organs such as lung, liver, brain or bone. Therefore early diagnosis remains crucial for improving clinical outcome for melanoma patients. Current chemotherapy and chemo-immunotherapy regimes have shown little clinical benefit with no improvement in overall survival. However, new advances in melanoma biology such as the discovery of predisposed gene signatures and key somatic events have changed clinical practice. New therapeutic approaches are being tested or have been approved by the FDA/EMA recently including targeted therapies, such as BRAF- and MEK-inhibitors, and novel immunotherapies, such as anti-CTLA4 or anti-PD1 therapies. For these therapies an improvement of progression-free and overall survival has been seen in patients with advanced non-resectable melanoma. The following review summarizes recent therapeutic options after the ASCO and ESMO annual meetings 2014 for the treatment of malignant melanoma.